MedTrace Logo

PTH - Preemptive Treatment for Herpesviridae

NCT02152358 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 317

Last updated 2023-04-06

No results posted yet for this study

Summary

The aim of this study is to show that a preemptive treatment by ganciclovir (for positive CMV viremia) or aciclovir (for positive HSV oro-pharyngeal PCR) is able to increase the number of ventilator-free days at Day 60.

Conditions

  • Viral Pneumonia

Interventions

DRUG

Aciclovir

Intravenous 15 mg/kg/d during 14 days

DRUG

Ganciclovir

intravenous 10 mg/kg/d for 14 days

DRUG

Placebo

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Principal Investigators

  • Laurent Papazian, MD, PhD · APHM - AMU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-05
Primary Completion
2018-04-21
Completion
2023-04-05

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02152358 on ClinicalTrials.gov